DE60023465D1 - Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser - Google Patents
Pharmazeutische formulierungen mit verbesserter löslichkeit in wasserInfo
- Publication number
- DE60023465D1 DE60023465D1 DE60023465T DE60023465T DE60023465D1 DE 60023465 D1 DE60023465 D1 DE 60023465D1 DE 60023465 T DE60023465 T DE 60023465T DE 60023465 T DE60023465 T DE 60023465T DE 60023465 D1 DE60023465 D1 DE 60023465D1
- Authority
- DE
- Germany
- Prior art keywords
- active agent
- stabilized
- formulation
- composition
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 239000013543 active substance Substances 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12591499P | 1999-03-24 | 1999-03-24 | |
US125914P | 1999-03-24 | ||
US14968099P | 1999-08-19 | 1999-08-19 | |
US149680P | 1999-08-19 | ||
PCT/US2000/007298 WO2000056726A1 (en) | 1999-03-24 | 2000-03-20 | Improved aqueous solubility pharmaceutical formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60023465D1 true DE60023465D1 (de) | 2005-12-01 |
DE60023465T2 DE60023465T2 (de) | 2006-07-20 |
Family
ID=26824087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60023465T Expired - Fee Related DE60023465T2 (de) | 1999-03-24 | 2000-03-20 | Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser |
Country Status (14)
Country | Link |
---|---|
US (3) | US6497905B1 (de) |
EP (1) | EP1163234B1 (de) |
JP (1) | JP2003531099A (de) |
CN (1) | CN1156461C (de) |
AT (1) | ATE307808T1 (de) |
AU (1) | AU3900300A (de) |
BR (1) | BR0009176A (de) |
CA (1) | CA2362728C (de) |
DE (1) | DE60023465T2 (de) |
DK (1) | DK1163234T3 (de) |
ES (1) | ES2251985T3 (de) |
IL (2) | IL145140A0 (de) |
TW (1) | TWI245644B (de) |
WO (1) | WO2000056726A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2381453A (en) * | 1999-08-31 | 2003-05-07 | Bradford Particle Design Ltd | Active/polymer coformulations |
CA2406383A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | A.beta.42 lowering agents |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
EP1642571A3 (de) * | 2000-12-22 | 2007-06-27 | Baxter International Inc. | Herstellungsverfahren für Submikronpartikeln |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6663897B2 (en) | 2001-02-06 | 2003-12-16 | Dsm Ip Assets B.V. | Oral itraconazole formulations and methods of making the same |
US8071133B2 (en) * | 2001-08-20 | 2011-12-06 | Stiefel Laboratories, Inc. | Oral dosage forms of water insoluble drugs and methods of making the same |
KR20040078661A (ko) * | 2002-01-08 | 2004-09-10 | 캔 테크놀로지스 인코포레이티드 | 소수성 고융점 화합물 및 지질의 혼합물로의 코팅에 의한캡슐화 |
ZA200502496B (en) | 2002-02-28 | 2005-10-12 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) * | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP1594467A4 (de) | 2002-07-05 | 2008-10-22 | Collegium Pharmaceutical Inc | Missbrauch verhindernde pharmazeutische zusammensetzungen von opioiden und anderen medikamenten |
DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
US20040086567A1 (en) * | 2002-10-30 | 2004-05-06 | Pawan Seth | Bioequivalent composition of itraconazole and a hydrophilic polymer |
EP1603548A4 (de) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen |
MXPA06000178A (es) * | 2003-07-01 | 2006-04-11 | Pharmacia & Upjohn Co Llc | Solidos modulados en la fase de difusion. |
HU227142B1 (en) * | 2003-07-02 | 2010-08-30 | Egis Gyogyszergyar Nyilvanosan | Capsule of improved release containing fluconazole |
EP1651195A4 (de) * | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | Pharmazeutische verfahren, dosierschemata und dosierformen zur behandlung von alzheimerkrankheit |
GB0319797D0 (en) * | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
EP1669345A4 (de) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | Esterderivate und deren medizinische verwendung |
US7413690B1 (en) | 2003-10-29 | 2008-08-19 | The University Of Mississippi | Process and apparatus for producing spherical pellets using molten solid matrices |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
AU2005241023A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
HUE037643T2 (hu) | 2004-06-12 | 2018-09-28 | Collegium Pharmaceutical Inc | Visszaélésre nem alkalmas gyógyszerkészítmények |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
CA2618985A1 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
WO2006046623A1 (ja) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
CN100430055C (zh) * | 2005-11-11 | 2008-11-05 | 天津泰普药品科技发展有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
JP2007308479A (ja) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 固体分散体製剤 |
US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
GB0818403D0 (en) * | 2008-10-08 | 2008-11-12 | Univ Leuven Kath | Aqueous electrophoretic deposition |
EP2334845A2 (de) * | 2008-10-06 | 2011-06-22 | Katholieke Universiteit Leuven K.U. Leuven R&D | Funktionelle schichten von biomolekülen und lebenden zellen und neues system zu ihrer herstellung |
EP2376068A2 (de) | 2008-12-15 | 2011-10-19 | Banner Pharmacaps, Inc. | Verfahren zur verbesserung der freisetzung und absorption von wasserunl?slichen wirkstoffen |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP2515879A4 (de) * | 2009-12-22 | 2014-04-02 | Fmc Corp Inc | Feinpartikel-croscarmellose und ihre verwendungen |
EP2601973A1 (de) * | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Trockenpulverformulierung eines Azolderivats zum Inhalieren |
JP2014122328A (ja) * | 2012-11-22 | 2014-07-03 | Shin Etsu Chem Co Ltd | 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法 |
GB201602579D0 (en) * | 2016-02-12 | 2016-03-30 | Mihranyan Albert | New compositions |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2907460A1 (de) * | 1978-03-07 | 1979-09-13 | Sandoz Ag | Neue resorbierbare galenische kompositionen |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US5118799A (en) | 1987-05-12 | 1992-06-02 | Pharmacin Corporation | Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate |
EP0462066A1 (de) | 1990-06-15 | 1991-12-18 | Warner-Lambert Company | Amorphes Gemfibrozil |
JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
US5208015A (en) | 1991-07-23 | 1993-05-04 | Bristol-Myers Squibb Company | Topical anti-fungal agents having anti-inflammatory activity |
US5200195A (en) | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
WO1993015719A1 (en) | 1992-02-12 | 1993-08-19 | Janssen Farmaceutici S.P.A. | Liposomal itraconazole formulations |
PT631578E (pt) | 1992-03-18 | 2001-11-30 | Janssen Pharmaceutica Nv | Estereoisomeros de itraconazol e saperconazol |
PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
IT1256386B (it) * | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
PH31594A (en) | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2722984B1 (fr) | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
US5976555A (en) * | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
JP3310299B2 (ja) | 1995-11-23 | 2002-08-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 溶融−押し出しにより調製されるシクロデキストリンの固体混合物 |
US5646151A (en) * | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
EP0904060B1 (de) * | 1996-05-20 | 2003-12-10 | Janssen Pharmaceutica N.V. | Fungizide mittel mit verbesserter bioverfügbarkeit |
US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
ZA9711732B (en) * | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
RU2218153C2 (ru) | 1997-03-26 | 2003-12-10 | Жансен Фармасетика Н.В. | Драже, имеющее ядро, покрытое противогрибковым средством и полимером |
US5813416A (en) | 1997-04-03 | 1998-09-29 | Rudolph; James M. | File with sanitizing agent |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
KR19990001564A (ko) | 1997-06-16 | 1999-01-15 | 유충식 | 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제 |
-
2000
- 2000-03-20 CN CNB008053995A patent/CN1156461C/zh not_active Expired - Fee Related
- 2000-03-20 JP JP2000606587A patent/JP2003531099A/ja not_active Ceased
- 2000-03-20 AT AT00918139T patent/ATE307808T1/de not_active IP Right Cessation
- 2000-03-20 DE DE60023465T patent/DE60023465T2/de not_active Expired - Fee Related
- 2000-03-20 AU AU39003/00A patent/AU3900300A/en not_active Abandoned
- 2000-03-20 EP EP00918139A patent/EP1163234B1/de not_active Expired - Lifetime
- 2000-03-20 WO PCT/US2000/007298 patent/WO2000056726A1/en active IP Right Grant
- 2000-03-20 IL IL14514000A patent/IL145140A0/xx active IP Right Grant
- 2000-03-20 DK DK00918139T patent/DK1163234T3/da active
- 2000-03-20 ES ES00918139T patent/ES2251985T3/es not_active Expired - Lifetime
- 2000-03-20 US US09/528,624 patent/US6497905B1/en not_active Expired - Fee Related
- 2000-03-20 BR BR0009176-6A patent/BR0009176A/pt active Pending
- 2000-03-20 CA CA002362728A patent/CA2362728C/en not_active Expired - Fee Related
- 2000-05-10 TW TW089105331A patent/TWI245644B/zh not_active IP Right Cessation
-
2001
- 2001-06-21 US US09/886,100 patent/US6379707B2/en not_active Expired - Fee Related
- 2001-06-21 US US09/886,493 patent/US6511681B2/en not_active Expired - Fee Related
- 2001-08-27 IL IL145140A patent/IL145140A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE307808T1 (de) | 2005-11-15 |
CA2362728A1 (en) | 2000-09-28 |
JP2003531099A (ja) | 2003-10-21 |
EP1163234A1 (de) | 2001-12-19 |
BR0009176A (pt) | 2001-12-18 |
CN1379768A (zh) | 2002-11-13 |
TWI245644B (en) | 2005-12-21 |
EP1163234A4 (de) | 2003-05-02 |
US6511681B2 (en) | 2003-01-28 |
AU3900300A (en) | 2000-10-09 |
US6497905B1 (en) | 2002-12-24 |
DE60023465T2 (de) | 2006-07-20 |
DK1163234T3 (da) | 2006-02-27 |
ES2251985T3 (es) | 2006-05-16 |
WO2000056726A1 (en) | 2000-09-28 |
US20020037324A1 (en) | 2002-03-28 |
CN1156461C (zh) | 2004-07-07 |
CA2362728C (en) | 2009-06-23 |
US20020012706A1 (en) | 2002-01-31 |
IL145140A (en) | 2006-08-20 |
US6379707B2 (en) | 2002-04-30 |
EP1163234B1 (de) | 2005-10-26 |
IL145140A0 (en) | 2002-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60023465D1 (de) | Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser | |
ES2561108T3 (es) | Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo | |
CY1120513T1 (el) | Υψηλης συμπυκνωσης συνθεση μινοξιδιλης | |
ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
PE20001049A1 (es) | Complejos estables de compuestos escasamente solubles | |
ITMI20021392A1 (it) | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' | |
ES2193658T3 (es) | Procedimiento para la preparacion de formulaciones acuosas para uso oftalmico. | |
YU23599A (sh) | Stabilizovani antihistaminski sirup | |
EA200000154A1 (ru) | Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях | |
CA2414063A1 (en) | Highly concentrated stable meloxicam solutions | |
MXPA05005046A (es) | Formulaciones parasiticidas topicas y metodos de tratamiento. | |
DE60017361D1 (de) | Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin | |
MXPA02001804A (es) | Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso. | |
CA2380757A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
PE20030545A1 (es) | Formulaciones de jarabe de ribavirina | |
ATE245968T1 (de) | Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung | |
WO2002009717A1 (fr) | Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif | |
EP1219296A4 (de) | Mittel zur hemmung der sebumproduktion | |
ATE291421T1 (de) | Pharmazeutische, ramipril enthaltende brauseformulierung | |
WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
ATE275577T1 (de) | Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung | |
NZ505080A (en) | Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid | |
ATE258046T1 (de) | Pharmazeutische, metamizol enthaltende brauseformulierung | |
AU2001258859A1 (en) | Pralmorelin-containing nasal drop preparations | |
WO2005123085A1 (es) | Solución acuosa de risperidona para administración oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |